HIV-1 DNA predicts disease progression and post-treatment virological control

In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite antiretroviral therapy (ART). With the aim of identifying individuals in whom ART might induce a period of viraemic control on stopping therapy, we hypothesised that quantification of the pool of latently infected cells in primary HIV-1 infection (PHI) would predict clinical progression and viral replication following ART. We measured HIV-1 DNA in a highly characterised randomised population of individuals with PHI. We explored associations between HIV-1 DNA and immunological and virological markers of clinical progression, including viral rebound in those interrupting therapy. In multivariable analyses, HIV-1 DNA was more predictive of disease progression than plasma viral load and, at treatment interruption, predicted time to plasma virus rebound. HIV-1 DNA may help identify individuals who could safely interrupt ART in future HIV-1 eradication trials. Clinical trial registration: ISRCTN76742797 and EudraCT2004-000446-20 DOI: http://dx.doi.org/10.7554/eLife.03821.001

[1]  John Frater,et al.  Low copy target detection by Droplet Digital PCR through application of a novel open access bioinformatic pipeline, ‘definetherain’ , 2014, Journal of virological methods.

[2]  Robert F. Siliciano,et al.  Novel ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo , 2014, Nature Medicine.

[3]  R. Phillips,et al.  HIV-1-specific CD4+ responses in primary HIV-1 infection predict disease progression , 2014, AIDS.

[4]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[5]  M. Hudgens,et al.  Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART , 2014, PLoS pathogens.

[6]  J. Kappes,et al.  High-Multiplicity HIV-1 Infection and Neutralizing Antibody Evasion Mediated by the Macrophage-T Cell Virological Synapse , 2013, Journal of Virology.

[7]  D. Richman,et al.  Absence of detectable HIV-1 viremia after treatment cessation in an infant. , 2013, The New England journal of medicine.

[8]  P. Kaleebu,et al.  Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy , 2013, PloS one.

[9]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[10]  A. LaCasce,et al.  Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. , 2013, The Journal of infectious diseases.

[11]  R. Siliciano,et al.  Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay , 2013, PLoS pathogens.

[12]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[13]  R. Siliciano,et al.  Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies , 2013, PLoS pathogens.

[14]  Steve Kaye,et al.  Short-course antiretroviral therapy in primary HIV infection. , 2013, The New England journal of medicine.

[15]  B. Clotet,et al.  A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication , 2013, Science Translational Medicine.

[16]  髙折 晃史,et al.  19th Conference on Retroviruses and Opportunistic Infections , 2012 .

[17]  G. Palù,et al.  Baseline Cellular HIV DNA Load Predicts HIV DNA Decline and Residual HIV Plasma Levels during Effective Antiretroviral Therapy , 2011, Journal of Clinical Microbiology.

[18]  J. Singer,et al.  A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune , 2011, AIDS.

[19]  J. Farrar,et al.  Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. , 2011, AIDS.

[20]  A. Bhandoola,et al.  Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. , 2011, Virology.

[21]  C. Rouzioux,et al.  A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir , 2010, Journal of medical virology.

[22]  Thierry Prazuck,et al.  Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection , 2010, AIDS.

[23]  Jianqing J. Yu,et al.  Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. , 2009, Methods.

[24]  Avettand‐Fènoël Véronique,et al.  LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01) , 2009 .

[25]  C. Rouzioux,et al.  LTR Real-Time PCR for HIV-1 DNA Quantitation in Blood Cells for Early Diagnosis in Infants Born to Seropositive Mothers Treated in HAART Area ( ANRS CO 01 ) , 2008 .

[26]  M. Terry.  HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults. , 2008 .

[27]  C. Rouzioux,et al.  HIV-1 DNA in Peripheral Blood Mononuclear Cells Is Strongly Associated With HIV-1 Disease Progression in Recently Infected West African Adults , 2008, Journal of acquired immune deficiency syndromes.

[28]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[29]  Lawrence Corey,et al.  Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. , 2007, The Journal of infectious diseases.

[30]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .

[31]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[32]  P. Morlat,et al.  CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  D. Havlir,et al.  Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. , 2005, The Journal of infectious diseases.

[34]  R. Siliciano,et al.  Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. , 2005, Methods in molecular biology.

[35]  T. Perneger,et al.  Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions , 2004, AIDS.

[36]  D. Émilie,et al.  Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. , 2003, The Journal of infectious diseases.

[37]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[38]  S. Hammer,et al.  Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. , 2003, The Journal of infectious diseases.

[39]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[41]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[42]  K. Harada,et al.  Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.

[43]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.